glp-1 next generation Next-Gen after Ozempic: Retatrutide to Orforglipron What is the pipeline for

I hope these resources empower you or your healthcare team to make informed decisions regarding STDEI GLP-1 therapy

Sommer F, Bckhed F

Many of these employers have considered scaling back coverage of GLP-1 agonists for weight loss, or in some cases, employers are adding or strengthening coverage requirements

[4] [6] Importantly, no clear association has been established between the heart rate increase with GLP-1 therapy and adverse cardiovascular outcomes

Liraglutide and semaglutide are approved in combination with a reduced-calorie diet and increased physical activity for chronic weight management under the brand names Saxenda and Wegovy

They chose Zepbound because emerging data suggested higher average weight loss with tirzepatide